Serum Institute shuns reports of commercializing Covishield, says will sell only after successful trial
"Covishield will be commercialised once the trials are proven successful and all the requisite regulatory approvals are in place", it added.
New Delhi: Serum Institute of India, has clarified that the current claims surrounding Covishield's availability in the media are completely false and conjectural. "Presently, the government has granted us permission to only manufacture the vaccine and stockpile it for future use", SII said in a statement. "Covishield will be commercialised once the trials are proven successful and all...
New Delhi: Serum Institute of India, has clarified that the current claims surrounding Covishield's availability in the media are completely false and conjectural.
"Presently, the government has granted us permission to only manufacture the vaccine and stockpile it for future use", SII said in a statement.
"Covishield will be commercialised once the trials are proven successful and all the requisite regulatory approvals are in place", it added.
"The phase-3 trials for the Oxford-AstraZeneca vaccine are still underway. And only once the vaccine is proven immunogenic and efficacious, SII will confirm its availability, officially", the statement said.
"Serum Institute of India, would like to clarify that the current claims surrounding Covishield's availability in the media are completely false and conjectural", it said.
The clarification came after reports that the vaccine would get commercialized in 73 days.
Read also: India Will Get COVID-19 Vaccine By 2020 End, Says Union Health Minister
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd